1,230,000 Shares in Teladoc Health, Inc. (NYSE:TDOC) Acquired by Maple Rock Capital Partners Inc.

Maple Rock Capital Partners Inc. bought a new position in Teladoc Health, Inc. (NYSE:TDOC) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,230,000 shares of the health services provider’s stock, valued at approximately $11,291,000. Teladoc Health makes up about 0.3% of Maple Rock Capital Partners Inc.’s holdings, making the stock its 26th biggest holding.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. lifted its holdings in shares of Teladoc Health by 221.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider’s stock valued at $51,865,000 after buying an additional 3,655,436 shares during the last quarter. Rubric Capital Management LP acquired a new stake in Teladoc Health in the second quarter valued at approximately $45,267,000. Clearline Capital LP lifted its stake in Teladoc Health by 395.6% in the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after acquiring an additional 3,483,665 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in Teladoc Health in the third quarter worth approximately $15,801,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Teladoc Health by 15.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,701,161 shares of the health services provider’s stock worth $15,617,000 after purchasing an additional 228,004 shares during the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Stock Down 4.9 %

NYSE TDOC opened at $10.94 on Wednesday. Teladoc Health, Inc. has a twelve month low of $6.76 and a twelve month high of $22.54. The stock has a market cap of $1.88 billion, a PE ratio of -1.90 and a beta of 0.97. The firm has a 50-day simple moving average of $9.48 and a 200 day simple moving average of $9.20. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The company had revenue of $640.51 million during the quarter, compared to the consensus estimate of $630.50 million. On average, research analysts forecast that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Insider Buying and Selling

In other Teladoc Health news, Director Thomas Mckinley bought 4,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average price of $7.69 per share, with a total value of $30,760.00. Following the completion of the purchase, the director now directly owns 39,077 shares in the company, valued at $300,502.13. The trade was a 11.40 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Carlos Nueno sold 2,389 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $11.93, for a total transaction of $28,500.77. Following the transaction, the insider now owns 2,890 shares of the company’s stock, valued at approximately $34,477.70. This represents a 45.25 % decrease in their position. The disclosure for this sale can be found here. 0.95% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on TDOC. Evercore ISI lifted their price objective on shares of Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. The Goldman Sachs Group initiated coverage on Teladoc Health in a research note on Friday, November 15th. They set a “buy” rating and a $14.00 price target for the company. Deutsche Bank Aktiengesellschaft increased their price objective on Teladoc Health from $10.00 to $12.00 and gave the company a “hold” rating in a report on Friday, November 1st. TD Cowen reduced their target price on Teladoc Health from $9.00 to $8.00 and set a “hold” rating for the company in a report on Thursday, October 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 target price on shares of Teladoc Health in a research report on Tuesday, August 20th. Fourteen analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $12.08.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.